Financings Of The Fortnight Ponders The Potential Of Mapping The Microbiome
This article was originally published in The Pink Sheet Daily
Plus news on recent financial activity by Tesaro, Omeros, Neviah Genomics and Aegerion Pharmaceuticals.
You may also be interested in...
Partnership is first investment under Merck Serono Ventures’ €10 million Israel Bioincubator Program.
Aegerion is preparing for an advisory committee meeting after submitting its LDL-C lowering oral drug lomitapide to FDA for patients with homozygous familial hypercholesterolemia. The NDA was submitted ahead of that for Isis/Genzyme’s injectable competitor, mipomersen.
With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.